Staidson (Beijing) Biopharmaceuticals Co. Ltd.

Staidson is a Beijing-based biopharmaceutical company engaged in the research, development and commercialization of therapeutic medicines. Its development capabilities include biologic products and other pharmaceutical approaches for diseases with unmet treatment needs. A company-affiliated development program has disclosed research involving a therapeutic biological product for hemophilia, while the wider business includes established prescription medicines. Staidson trades on the Shenzhen Stock Exchange under stock code 300204. Its corporate website identifies the company's principal operating address in Beijing, and exchange filings support the issuer and listed-security information.